When assessing patients with suspected prostate cancer metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated PSA,

PYLARIFY® reveals The clearer Picture.3-11

Not actual patients.

Piflufolastat F 18 Injection (PYLARIFY®)

NATIONAL COMPREHENSIVE 
CANCER NETWORK® (NCCN®) 
CATEGORY 2A* RECOMMENDED12

LEARN MORE

*Category 2A recommendations are made when based upon lower-level evidence there is uniform NCCN consensus that the intervention is appropriate.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Clarify with PYLARIFY®

  • PET imaging icon

    PET IMAGING:
    FOR ACCURACY6

  • PSMA targeting icon

    PSMA TARGETING:
    FOR PRECISION7-9

  • Fluorine-18 icon

    18F RADIOISOTOPE:
    FOR CLARITY5

  • Artificial Intelligence icon

    ARTIFICIAL INTELLIGENCE:
    FOR CONSISTENCY2

This combination brings superior diagnostic performance in assessing patients with suspected metastasis for initial definitive therapy or suspected recurrence based on elevated PSA, allowing you to better assess your patients' disease status.3,5,6,10

Compared to standard anatomic images.13       
In the setting of negative or equivocal standard imaging.14

PYLARIFY® data icon

See PYLARIFY® data in patients with high-risk PCa who were candidates for initial definitive therapy

Learn More
Trial results icon

See trial results in patients with biochemically recurrent prostate cancer

Learn More
How PYLARIFY® works icon

Learn how PYLARIFY® works

Learn More
Find a PYLARIFY Imaging Center

Find a PYLARIFY® imaging center near you

Learn More

The incidence of prostate cancer is rising and  resulting mortality rates remain significant15,16

Approximately 248,530 new prostate cancer cases will be diagnosed in 2021

new prostate cancer cases will be diagnosed in 202315,16

Approximately 34,130 PCa deaths will occur in 2021

deaths will occur in 2023 due to PCa, the second leading cause of cancer death in American men15,16

Accurate initial assessment of a patient's disease is critical because high-risk PCa is more likely to be advanced at diagnosis and/or relapse than low-risk PCa12,17,18

5-year relative survival rate for patients diagnosed with localized prostate cancer approaches 100%, however, if distant metastasis is present at the time of diagnosis, the 5-year survival rate has been reported to be 32%19

5-year survival rates of localized, regional, and distant prostate cancer
PET/CT scan icon

Standard imaging offers limited accuracy in PCa assessment, potentially compromising therapeutic decision-making20,21

  • Although bone scans and CT scans can detect bone metastases, they lack sensitivity for early lesion detection6
  • Standard imaging offers limited utility in detecting recurrent lesions at PSA levels <1.0 ng/mL22
  • CT scans and MRIs depend on size to detect lesions, and are therefore less likely to detect metastatic tumors between 4 mm and 8 mm6,13
  • Bone remodeling in response to treatment may lead to false positives on MRI images6
PSMA PET CAN DETECT WHAT CONVENTIONAL IMAGING DID NOT23

Tom Boike, MD, MMM, discusses the limitations of conventional imaging for prostate cancer compared to the advances of PSMA PET imaging.

PET imaging§ has the potential to improve disease localization compared to standard imaging, thus enhancing therapeutic decision-making20,21,23

§With an appropriate tracer and combined with CT or MRI.


  • PSMA PET/CT can detect lesions between 4 mm and 8 mm, and therefore has a higher detection rate6,13
    • Because up to 80% of nodal metastases in PCa are smaller than 8 mm in size, PSMA PET/CT is a promising imaging modality6
  • PSMA PET/CT is also effective at lower PSA levels; the rate of detection of nodal metastases has been reported to be 46% when PSA was <0.2 ng/mL6

PSMA PET IMAGING IMPROVES DISEASE ASSESSMENT

which reduces the risk of undertreatment (leading to disease spread) and overtreatment (leading to unnecessary toxicity or surgery)24,25

LEARN ABOUT PYLARIFY®
FOR PCa IMAGING
PSMA PET IMAGING  HELPS IDENTIFY  CLEAR NEXT STEPS3-11

Ben Lowentritt, MD, FACS, recounts scenarios where PSMA PET imaging changed the course of patient care.

CT=computed tomography; MRI=magnetic resonance imaging; NCCN=National Comprehensive Cancer Network; PCa=prostate cancer; PET=positron emission tomography; PSMA=prostate-specific membrane antigen.

INDICATION & IMPORTANT
SAFETY INFORMATION

PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

References

  1. Data on file. Bedford, MA: Progenics Pharmaceuticals, Inc.; 2023.
  2. FDA clearance letter for aPROMISE X. Food and Drug Administration. April 29, 2022.
  3. PYLARIFY® [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company.
  4. Mena E, Lindenberg ML, Turkbey IB, et al. 18F-DCFPYL PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. J Nucl Med. 2020;61(6):881-889. doi:10.2967/jnumed.119.234799
  5. Werner RA, Derlin T, Lapa C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1-16. doi:10.7150/thno.37894
  6. Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019;11:1-14. doi:10.1177/1758835919876828
  7. Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020;20(1):1-8. doi:10.1186/s40644-020-0290-9
  8. Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296:44-55. doi:10.1148/radiol.2020191689
  9. Ceci F, Fanti S. PSMA PET/CT imaging in prostate cancer: why and when. Clin Transl Imaging. 2019;7:377-379. doi:10.1007/s40336-019-00348-x
  10. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [18F]DCFPYL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575-584. doi:10.1007/s11307-015-0866-0
  11. Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [18F]DCFPYL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565-574. doi:10.1007/s11307-015-0850-8
  12. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer. V.1.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed November 10, 2022. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  13. Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206(1):52-61. doi:10.1097/JU.0000000000001698
  14. Morris MJ, Rowe SP, Gorin MA, et al. Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27(13):3674-3682. doi:10.1158/1078-0432.CCR-20-4573
  15. Key statistics for prostate cancer. American Cancer Society. Updated January 12, 2022. Accessed November 21, 2022. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
  16. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7-33. doi:10.3322/caac.21708
  17. Wang Z, Ni Y, Chen J, et al. The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2020;18(1):42. doi:10.1186/s12957-020-01824-9
  18. Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308-323. doi:10.1038/nrclinonc.2014.68
  19. Cancer stat facts: prostate cancer. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Accessed November 21, 2022. https://seer.cancer.gov/statfacts/html/prost.html
  20. Hofman MS, Lawrentschuk N, Francis RJ, et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. doi:10.1016/S0140-6736(20)30314-7
  21. Rousseau E, Wilson D, Lacroix-Poisson F, et al. A prospective study on 18F-DCFPYL PSMA PET/CT imaging in biochemical recurrence of prostate cancer. J Nucl Med. 2019;60(11):1587-1593. doi:10.2967/jnumed.119.226381
  22. Taneja SS. Imaging in the diagnosis and management of prostate cancer. Rev Urol. 2004;6(3):101-113.
  23. Li R, Ravizzini GC, Gorin MA, et al. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(1):4-21. doi:10.1038/s41391-017-0007-8
  24. Park SY, Zacharias C, Harrison C, et al. Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology. 2018;288(2):495-505. doi:10.1148/radiol.2018172232
  25. Gorin MA, Rowe SP, Patel HD, et al. Prostate specific membrane antigen targeted 18F-DCFPYL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study. J Urol. 2018;199(1):126-132. doi:10.1016/j.juro.2017.07.070